Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population screening for isoniazid acetylator phenotype.

Pharmacoepidemiology and drug safety - 1 Jan 2000

Seifart H I, Parkin D P, Botha F J, Donald P R, Van Der Walt B J

Abstract excerpt

PURPOSE: To establish a useful method for acetylator phenotypification and therapeutic drug monitoring of patients receiving isoniazid. METHODS: Sixty patients with uncomplicated pulmonary tuberculosis were given a 5-mg/kg oral dose of isoniazid each. Plasma concentrations of isoniazid and its metabolite, acetyl-isoniazid, were determined by HPLC analyses at various post-dose times. From the isoniazid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Antitubercular Agents
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Availability

Share to Chromatography, High Pressure Liquid

Share to Drug Monitoring

Share to Isoniazid

Share to Tuberculosis, Pulmonary

Source

Identifiers

PMID: 11499851
DOI: 10.1002/pds.570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population screening for isoniazid acetylator phenotype.PMID 11499851Read ↗

Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?Semantic proximity Read ↗

Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Semantic proximity Read ↗

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.Semantic proximity Read ↗

Determination of the acetylator phenotype in Moroccan tuberculosis patients using isoniazid as metabolic probe.Semantic proximity Read ↗

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.Semantic proximity Read ↗

A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Semantic proximity Read ↗

Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.Semantic proximity Read ↗

Acetylation Variability in Elderly Tunisians: Implications for Isoniazid Dose Individualization.Semantic proximity Read ↗

Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.Semantic proximity Read ↗

Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis.Semantic proximity Read ↗

Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.Semantic proximity Read ↗

Isoniazid acetylation metabolic ratio during maturation in children.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.